Orexigen Therapeutics, Inc. has recalled 18,895 bottles of Contrave (naltrexone HCl and bupropion HCl) extended-release tablets because of a container packaging defect. Contrave is a prescription weight-loss medication, and this specific recall affects 120-count bottles of 8mg/90 mg strength tablets. Consumers should be aware that defects in medication packaging can impact the stability or integrity of the drug. If you have this medication, you should consult with your healthcare provider or pharmacist regarding the continued use of your current supply.
The packaging defect may compromise the protective seal or structural integrity of the container, potentially exposing the tablets to moisture or environmental factors that could affect how the medication works. While the risk level is currently classified as low, compromised packaging in extended-release medications can lead to sub-optimal treatment outcomes.
Guidance and refund for unused medication.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.